China Task Force

The China Task Force focuses on advancing PVD care and research across China. The Task Force brings together clinicians, researchers, and institutions to strengthen clinical practice, education, research, and multidisciplinary collaboration across PE, PH, and CTEPH.

Through PVRI, the Task Force promotes collaboration within China and internationally, supporting clinical training, technical exchange, scientific research, and talent development across China and the broader Asia-Pacific region.

Aims & Goals

The Task Force aims to drive technological progress in the field of pulmonary vascular medicine across China and the broader Asia-Pacific region in the following ways:

• strengthen and expand national registries and cohort studies for pulmonary embolism (PE), chronic thromboembolic pulmonary hypertension (CTEPH), pulmonary arterial hypertension (PAH), and PH associated with chronic lung diseases
• advance clinical diagnosis and treatment of PH and related pulmonary vascular conditions
• support professional training and education for healthcare providers
• promote translational and clinical research, including the integration of emerging technologies
• foster domestic and international academic exchange through collaboration with PVRI and global partners
• support the integration of artificial intelligence and innovative vascular interventional techniques into clinical practice and research
• strengthen capacity building for the prevention, diagnosis, and treatment of PE
• support the development of the Pulmonary Vascular Intervention Alliance and the CTEPH Alliance
• convene a working meeting of the PVRI China Centre alongside the the National Conference on Pulmonary Embolism and Pulmonary Vascular Diseases in Harbin, China, from 28–30 August 2026
   

Five strategic priorities

1. Clinical education and guideline dissemination
   We plan to organize PVRI-themed sessions at major national meetings and launch implementation workshops on PE and PH guidelines across selected regional centres in China
2. Collaborative research and registry development
   Building on our existing registry work, we aim to develop a multicentre observational registry for PAH and CTEPH, promote data sharing among Chinese centres, and initiate collaborative clinical research projects
3. Clinical capacity and skills training
   We intend to arrange visiting expert programs, short-term fellow exchanges, and practical workshops focused on advanced imaging, hemodynamic assessment in PAH, and interventional approaches to CTEPH
4. Young investigator exchange and collaboration
   We will establish regular webinar series, in-person exchange activities, and project incubators to support early-career researchers in joint grant applications and publications related to pulmonary vascular disorders
5. Thrombosis and Circulation Research
   We are also supporting the launch of a new international journal, Thrombosis and Circulation Research, which will focus on thrombosis, vascular biology, and circulatory medicine, with a special emphasis on translational research in pulmonary vascular diseases

Recent activities

In 2025 the China Task Force has:

• expanded a national registry network for venous thromboembolism (VTE), PE, and CTEPH. This comprised of 153 PE centres, 123 VTE centres, 20 CTEPH centres, and 39 specialised right heart catheterisation and interventional centres — enrolling over 100,000 patients across multiple cohorts
• contributed to international research collaborations, including the TEAM registry and the GoDeep study group
• hosted the PVRI–China Seminar in Kunming, China. The had in-person participation from PVRI experts and over 1,000 attendees, strengthening academic exchange and laying foundations for future collaborative research.
   

If you are interested in joining this Task Force, please get in touch.